We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-26.78%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$765M
AUM Growth
-$373M
Cap. Flow
-$25.7M
Cap. Flow %
-3.36%
Top 10 Hldgs %
52.72%
Holding
58
New
1
Increased
22
Reduced
25
Closed
3

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$15.8M
2
KURA icon
Kura Oncology
KURA
+$10.1M
3
MRUS
Merus
MRUS
+$8.69M
4
VSTM icon
Verastem
VSTM
+$7.77M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$7.27M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$26M
2
ARRY
Array Biopharma Inc
ARRY
+$23.5M
3
XNCR icon
Xencor
XNCR
+$8.96M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.76M
5
CYTK icon
Cytokinetics
CYTK
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 83.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGLS
51
DELISTED
Regulus Therapeutics
RGLS
$979K 0.13%
105,194
-8,849
-8% -$147K
VIRX
52
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$951K 0.12%
65,367
+17,235
+36% +$703K
RLM
53
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$668K 0.09%
360,866
– –
LOXO
54
DELISTED
Loxo Oncology, Inc
LOXO
$552K 0.07%
3,944
-145
-4% -$22K
IONS icon
55
Ionis Pharmaceuticals
IONS
$8.57B
$508K 0.07%
9,399
-510,601
-98% -$26M
ZYME icon
56
Zymeworks
ZYME
$1.61B
– –
-19,804
Closed -$311K
KDNY
57
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-57,555
Closed -$2.12M
TSRO
58
DELISTED
TESARO, Inc.
TSRO
– –
-140,000
Closed -$5.46M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2018 Portfolio in Review

As of Q4 2018, BVF Inc held 58 positions worth $765M, down 33% from $1.14B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

BVF Inc withdrew a net $25.7M in Q4 2018, closing 3 positions and reducing 25 holdings. Its most notable exit was TESARO, Inc., an estimated $5.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier.

Against the trend, BVF Inc opened a new position in Eiger BioPharmaceuticals, Inc. worth $6.86M.

  • BVF Inc's largest Q4 2018 buy was Eiger BioPharmaceuticals, Inc.: 22,500 shares worth $6.86M.
  • BVF Inc added most to Arcus Biosciences in Q4 2018, an estimated $15.8M increase.
  • BVF Inc's biggest Q4 2018 reduction was Ionis Pharmaceuticals, cutting an estimated $26M.
  • BVF Inc fully exited TESARO, Inc. in Q4 2018, selling an estimated $5.46M.
  • BVF Inc's ten largest holdings make up 53% of its $765M portfolio in Q4 2018.
  • BVF Inc opened 1 new position and closed 3 in Q4 2018.
  • BVF Inc's portfolio value fell 33% quarter-over-quarter to $765M.

Based on BVF Inc's 13F filing for Q4 2018, filed 14 Feb 2019.